First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021

Cited by 1,205 works. doi:10.1016/s0140-6736(20)32714-8 Open-access PDF

Authors

References